Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Mar 28;143(13):1206-1207.
doi: 10.1182/blood.2023023448.

GPR56 in GVL: marker or mechanism?

Audra N Iness  1   2 , Pavan Bachireddy  2
Affiliations
Editorial

GPR56 in GVL: marker or mechanism?

Audra N Iness et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: P.B. declares equity in Agenus, Amgen, Johnson & Johnson, Exelixis, and BioNTech and receives research support from Allogene Therapeutics. A.N.I. declares no competing financial interests.

Figures

None
CD8+ T cells derived from patients who remained in CR after alloSCT for AML are characterized by a GPR56+, cytotoxic phenotype in contrast to those derived from patients who later relapsed with AML that exhibit GPR56−, immune-suppressive regulatory states. Professional illustration by Patrick Lane, ScEYEnce Studios.
See this image and copyright information in PMC

Comment on

References

    1. Mathioudaki A, Wang X, Sedloev DN, et al. The remission status of AML patients post alloSCT is associated with a distinct single-cell bone marrow T cell signature. Blood. 2024;143(13):1269–1281. - PubMed
    1. Zeiser R, Vago L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood. 2019;133(12):1290–1297. - PubMed
    1. Bachireddy P, Hainz U, Rooney M, et al. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood. 2014;123(9):1412–1421. - PMC - PubMed
    1. Bachireddy P, Azizi E, Burdziak C, et al. Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep. 2021;37(6) - PMC - PubMed
    1. Penter L, Zhang Y, Savell A, et al. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021;137(23):3212–3217. - PMC - PubMed